Ein Paarvergleich findet Originalpassagen, die den anderen Wirkstoff wörtlich nennen. Aussagen gelten für das jeweilige Präparat und seine Formulierung. Klassenbegriffe und abweichende Synonyme können fehlen. Kein Treffer bedeutet nicht, dass keine Wechselwirkung besteht.
RxNorm 05-Oct-2026 · geprüft 2026-10-25 · 1009 Präparate · 54812 Quellenpassagen · 148 strukturierte Aussagen. Automatisch aktualisiert, ohne menschliche Freigabe.
Wechselwirkungen · Vocabria
400 mg Vocabria 400 mg prolonged-release suspension for injection 600 mg Vocabria 600 mg prolonged-release suspension for injection · Abschnitt 4.5 · PDF-Seite 10
HOS-143423 · Präparat HOS-099004
Rifapentine Cabotegravir Rifapentine may significantly decrease
cabotegravir plasma concentrations. Concomitant
use is contraindicated (see section 4.3).
Rifabutin Cabotegravir Rifabutin may decrease cabotegravir plasma
AUC 21% concentration. Concomitant use should be avoided.
Cmax 17%
Cτ 26%
Oral contraceptives
Ethinyl estradiol (EE) EE Cabotegravir did not significantly change ethinyl
and Levonorgestrel AUC 2% estradiol and levonorgestrel plasma concentrations
(LNG) Cmax 8% to a clinically relevant extent. No dose adjustment
Cτ 0% of oral contraceptives is necessary when co-
administered with Vocabria.
LNG
AUC 12%
Cmax 5%
Cτ 7%
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): rifabutin (HOS-086262) levonorgestrel (HOS-089677) estradiol (HOS-090751) ethinyl estradiol (HOS-088135) rifapentine (HOS-116386)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-09-09T14:50:00Z · SHA-256 5a6802905e0f35577ea123d161d3a8ece2c09d33762d2d6c349b5a0a60e5d7b9 · Passage ea6db5668e2a573251763d2ba581518b6a1e7083b6e1d58191ca040222c7423c · Zeichen 5322–6569 im Abschnitt
Wechselwirkungen · Vocabria
Vocabria 30 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 32–33
HOS-143460 · Präparat HOS-099004
32
Rilpivirine
AUC 1%
Cmax 4%
Cτ 8%
Anticonvulsants
Carbamazepine Cabotegravir Metabolic inducers may significantly decrease
Oxcarbazepine cabotegravir plasma concentrations, concomitant
Phenytoin use is contraindicated (see section 4.3).
Phenobarbital
Antacids
Antacids (e.g. Cabotegravir Co-administration of antacid supplements has the
magnesium, potential to decrease oral cabotegravir absorption
aluminium, or and has not been studied.
calcium) Antacid products containing polyvalent cations are
recommended to be administered at least 2 hours
before or 4 hours after oral Vocabria (see section
4.4).
Antimycobacterials
Rifampicin Cabotegravir Rifampicin significantly decreased cabotegravir
AUC 59% plasma concentration which is likely to result in
Cmax 6% loss of therapeutic effect. Dosing recommendations
for co-administration of Vocabria with rifampicin
have not been established and co-administration of
Vocabria with rifampicin is contraindicated (see
section 4.3).
Rifapentine Cabotegravir Rifapentine may significantly decrease
cabotegravir plasma concentrations, concomitant
use is contraindicated (see section 4.3).
Rifabutin Cabotegravir Rifabutin did not significantly change cabotegravir
AUC 21% plasma concentration. No dose adjustment is
Cmax 17% required.
Cτ 26% Prior to initiation of oral cabotegravir therapy, the
prescribing information for cabotegravir injection
should be consulted regarding concomitant use
with rifabutin.
Oral Contraceptives
Ethinyl estradiol (EE) EE Cabotegravir did not significantly change ethinyl
and Levonorgestrel AUC 2% estradiol and levonorgestrel plasma concentrations
(LNG) Cmax 8% to a clinically relevant extent. No dose adjustment
Cτ 0% of oral contraceptives is necessary when co-
administered with Vocabria tablets.
LNG
AUC 12%
Cmax 5%
Cτ 7%
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): phenobarbital (HOS-085617) carbamazepine (HOS-085618) rifabutin (HOS-086262) levonorgestrel (HOS-089677) estradiol (HOS-090751) ethinyl estradiol (HOS-088135) calcium (HOS-085615) rilpivirine (HOS-088090) rifapentine (HOS-116386) oxcarbazepine (HOS-110224) magnesium (HOS-085165) phenytoin (HOS-084531)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-09-09T14:50:00Z · SHA-256 5a6802905e0f35577ea123d161d3a8ece2c09d33762d2d6c349b5a0a60e5d7b9 · Passage e9af1304002578248baf17f23ad983e13ef7af9977659c21fcee2aebdfc977f2 · Zeichen 3494–7054 im Abschnitt
Wechselwirkungen · Dovprela (previously Pretomanid FGK)
Dovprela 200 mg tablet · Abschnitt 4.5 · PDF-Seite 6
HOS-144813 · Präparat HOS-099268
CYP3A4 inducers
Pretomanid is metabolized in part by CYP3A4. In consequence, exposure to pretomanid may be
reduced during co-administration with inducers of CYP3A4. In interaction studies of multiple-dose
pretomanid with multiple-dose rifampicin or efavirenz, the AUC0-24h of pretomanid was reduced by
66% or 35%, respectively. Due to the possibility of a reduction of the therapeutic effect of pretomanid
due to a decrease in systemic exposure, co-administration of pretomanid and moderate or strong
CYP3A4 inducers (e.g. efavirenz, etravirine, rifamycins including rifampicin, rifapentine and
rifabutin, carbamazepine, phenytoin, St. John’s wort (Hypericum perforatum)) used systemically
should be avoided (see section 4.4).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): carbamazepine (HOS-085618) rifabutin (HOS-086262) etravirine (HOS-088088) rifamycins (HOS-144814) rifapentine (HOS-116386) efavirenz (HOS-087947) phenytoin (HOS-084531)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-14T16:46:00Z · SHA-256 f4a7f0a8b4df86dce72356ee9b9c725ab35f6da93524ade713723e655c07a01c · Passage 6f0302909bcd34177d0142a40b832973a8921d8e64c13084cccdf1f95be35e34 · Zeichen 51–777 im Abschnitt
Wechselwirkungen · Abiraterone Mylan
Abiraterone Mylan 500 mg film-coated tablets Abiraterone Mylan 1000 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 6
HOS-146760 · Präparat HOS-099564
Strong inducers of CYP3A4 (e.g., phenytoin, carbamazepine, rifampicin, rifabutin, rifapentine,
phenobarbital, St John's wort [Hypericum perforatum]) during treatment are to be avoided, unless there
is no therapeutic alternative.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): phenobarbital (HOS-085617) carbamazepine (HOS-085618) rifabutin (HOS-086262) rifapentine (HOS-116386) phenytoin (HOS-084531)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-01-19T13:57:00Z · SHA-256 a224b8fadc2ad3e1b1af874d8687b8e3d6bb14c5f714b2308f5ba81c1b78da11 · Passage e0c8ae045308d4d105608587f84bfe851e7205d5e6feee4ad086074d717da542 · Zeichen 646–874 im Abschnitt
Wechselwirkungen · Akeega
Akeega 50 mg/500 mg film-coated tablets Akeega 100 mg/500 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 9
HOS-150305 · Präparat HOS-100288
Effects of other medicinal products on niraparib or abiraterone acetate
CYP3A4 inducers and inhibitors
Abiraterone is a CYP3A4 substrate. In a clinical study in healthy subjects pretreated with the strong
CYP3A4 inducer rifampicin, 600 mg daily for six days, followed by a single dose of abiraterone
acetate 1 000 mg, the mean plasma AUC∞ of abiraterone was decreased by 55%. Strong inducers of
CYP3A4 (e.g., phenytoin, carbamazepine, rifampicin, rifabutin, rifapentine, phenobarbital, St. John’s
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): niraparib (HOS-136825) acetate (HOS-088133) phenobarbital (HOS-085617) carbamazepine (HOS-085618) rifabutin (HOS-086262) rifapentine (HOS-116386) phenytoin (HOS-084531)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-03-17T15:30:00Z · SHA-256 1bec7f3e5f18e4fe578c0f49b6a9128776963f703a1a9503180dea643f434459 · Passage 5a39257e1810acd5e43bc7e19d038bcfdd51d101b51ec7daeaa4dc3afba10b0b · Zeichen 287–783 im Abschnitt
Wechselwirkungen · Balversa
Balversa 3 mg film-coated tablets Balversa 4 mg film-coated tablets Balversa 5 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 9
HOS-151047 · Präparat HOS-100442
Strong or moderate CYP3A4 inducers
Co-administration with carbamazepine, a strong CYP3A4 and weak CYP2C9 inducer leads to
decreased erdafitinib exposure. Mean ratios of Cmax and AUC∞ for erdafitinib was 65.4% (90% CI:
60.8, 70.5) and 37.7% (90% CI: 35.4, 40.2), respectively, when co-administered with carbamazepine
relative to erdafitinib alone. Avoid co-administration of Balversa with strong CYP3A4 inducers (such
as apalutamide, enzalutamide, lumacaftor, ivosidenib, mitotane, rifapentine, rifampicin,
carbamazepine, phenytoin, and St. John’s wort). If Balversa is co-administered with a moderate
CYP3A4 inducer (such as dabrafenib, bosentan, cenobamate, elagolix, efavirenz, etravirine, lorlatinib,
mitapivat, modafinil, pexidartinib, phenobarbital, primidone, repotrectinib, rifabutin, sotorasib,
telotristat ethyl), the dose should be cautiously increased by 1 to 2 mg and adjusted gradually every
two to three weeks based on clinical monitoring for adverse reactions, not to exceed 9 mg. If the
moderate CYP3A4 inducer is discontinued, the Balversa dose may be adjusted as tolerated (see
sections 4.2 and 4.4).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): lumacaftor (HOS-139029) phenobarbital (HOS-085617) modafinil (HOS-090546) carbamazepine (HOS-085618) rifabutin (HOS-086262) apalutamide (HOS-086212) sotorasib (HOS-147831) etravirine (HOS-088088) dabrafenib (HOS-109452) telotristat ethyl (HOS-141158) mitapivat (HOS-147878) mitotane (HOS-112479) elagolix (HOS-112109) lorlatinib (HOS-140195) rifapentine (HOS-116386) ivosidenib (HOS-112046) efavirenz (HOS-087947) bosentan (HOS-086291) phenytoin (HOS-084531) repotrectinib (HOS-151068) enzalutamide (HOS-116829) pexidartinib (HOS-150766) cenobamate (HOS-146930) primidone (HOS-090551)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-06-23T15:29:41Z · SHA-256 9ba94a293568a63e1d68e3b08064d69d982961a4e8105cf8a7ed2e20ea28400b · Passage 37f802579316593a43bdb4de7805a7ac6e6865a9f601ae60d32e15b61a221f1c · Zeichen 1417–2535 im Abschnitt
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.